Docket No.: PF-0628 USN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Connectioner for Patents, Washington, D.C. 20231

on December 12, 2001

Printed:

Clara Alcazar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title:

TRANSMEMBRANE 4 PROTEINS

Serial No.:

09/830,328

Filing Date:

To Be Assigned

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents

Box PCT

Washington, D.C. 20231

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

- 1. Return postcard;
- 2. Response to Notification to Comply with Requirements (2 pp.);
- 3. Copy of Notification to Comply with Requirements Under 35 CFR U.S. C. 371 dated October 17, 2001 ((3 pp.);
- 4. Submission Under 37 CFR § 1.821-1.825 Sequence Listing (1 pp); and
- 5. One (1) CRF Diskette containing the computer-readable information for the Sequence Listing.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 12 Dec 2001


Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive Palo Alto, California 94304 Phone: (650) 855-0555 Fax: (650) 849-8886

88709 1 : 09/830,328





Docket No.: PF-0628 USN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Box Sequence, Washington, D.C. 20231

on December 12, 2001

By: Clause Olice

Printed: Clara Alcazar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang et al.

Title:

TRANSMEMBRANE 4 PROTEINS

Serial No.:

09/830,328

Filing Date:

To Be Assigned

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Commissioner for Patents

Box PCT

Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (copy attached) mailed by the United States Patent and Trademark Office on October 17, 2001, Applicants submit the following documents to complete the filing for the above-identified patent application:

- 1. Submission Under 37 CFR §1.821-1.825 Sequence Listing (2 pages); and
- 2. One computer-readable diskette.

Applicants believe that a fee is not necessary with this transmittal. However, if the United States Patent and Trademark Office determines that additional fees are due or that an excess

Docket No.: PF-0628 USN

fee has been paid, the Patent Office is authorized to debit or credit (respectively) Deposit Account No. 09-0108.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 12 Dec 2001

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive

Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 849-8886

\$ 4 JAN 2002

Commissioner for Patents, Box PCT inited States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.				
	PIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/830328	TANG	Υ		PF-0628 USN
		Dri	ERNATIONAL /	OFFLICATION NO.
NCYTE GENOMICS 160 PORTER DRIVE PALO ALTO, CA 94304	COPY	PCT/US99/25499		
**************************************		LA. PILI	NG DATE	PRIORITY DATE
		29 OC	CT 99	29 OCT 98
			_	<i>-</i>

Due: 12.17.2001

DATE MAILED

17 OCT 2001

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT API-LICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1 821(c)
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation,
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help,
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation,

Christine S. Washington

Telephone: 703-305-3752